Can Medications Treat Dissociation? Evidence, Benefits, and Risks
Author: Angela Bogdanova · Published: October 9, 2026 · Editorial Policy
Research cluster: Dissociation & Dissociative Disorders · Written by Artificial Sapiens
Medication can help some people who experience dissociation, especially when depression, anxiety, posttraumatic stress disorder (PTSD), insomnia, or another treatable condition is also present. But the evidence for a medication that directly and reliably treats a dissociative disorder remains limited. The choice of treatment depends on what is causing the symptoms, which symptoms cause the greatest impairment, and whether a clinician has identified a specific disorder. There is no established medication cure for dissociative identity disorder (DID), dissociative amnesia, or depersonalization-derealization disorder (DPDR).
The distinction matters. A medication may reduce panic attacks while a person's sense of unreality persists. It may improve depressed mood without resolving memory gaps. It may also cause dizziness, emotional blunting, confusion, or perceptual changes that resemble or intensify the complaint. This review explains what medication trials actually found, which prescriptions are used for associated conditions, and how to weigh possible benefits against risks. It is educational information, not a recommendation to start, stop, or adjust a drug.
The short answer: What can medication do for dissociation?
The American Psychiatric Association's clinical overview states that there are no medications that directly treat DID symptoms, although medications may treat related problems such as depression. The ISSTD adult treatment guideline likewise describes medication as adjunctive rather than the primary treatment for dissociative processes. These statements do not mean medication is never clinically appropriate; they describe the gap between using a medicine for a recognized target and proving it reverses dissociation itself.
A 2019 systematic review of pharmacotherapy included five randomized controlled trials with 214 participants across differing dissociative symptoms and diagnostic contexts. Its pooled risk ratio for response was 1.59, but the 95% confidence interval was 0.76–3.30 and the reported P value was 0.21. The estimate was imprecise and did not establish a reliable overall treatment effect. The included populations, drugs, and outcomes were heterogeneous; results cannot be generalized to every dissociative disorder.
A 2023 systematic review of depersonalization-derealization treatments identified 41 studies totaling 300 participants, including only four randomized controlled trials; many other reports were case studies or case series. The authors judged the quality and quantity of evidence generally low. A promising case report, small nonblinded trial, or pooled effect across different diagnoses therefore cannot establish a standard medication regimen.
What exactly is being treated?
Dissociation describes experiences of disconnection involving awareness, memory, identity, feelings, bodily experience, or perception. Brief episodes can occur during fatigue, overwhelming emotion, or intense absorption. A dissociative symptom becomes a clinical concern when it is persistent, recurrent, highly distressing, unsafe, or functionally impairing. A diagnosis follows an assessment, including possible medical, sleep-related, medication-related, and substance-related explanations. The WHO ICD-11 clinical descriptions and diagnostic requirements and DSM-5-TR provide clinical classifications with some differences in organization.
Depersonalization and derealization
Depersonalization can feel like detachment from one's body, thoughts, or emotions; derealization can make surroundings seem unreal, distant, or dreamlike. In DPDR disorder, the experience is persistent or recurrent, distressing or impairing, and reality testing generally remains intact. A person can know that the world is real while feeling profoundly disconnected from it. Panic, stress, mood disorders, sleep loss, substances, migraines, and seizure disorders may generate overlapping sensations and require differential assessment.
Dissociative identity disorder and other specified dissociative disorder
DID involves clinically significant identity disruption and discontinuity, together with recurrent gaps in everyday or autobiographical memory, interpreted within the relevant diagnostic framework. Other specified dissociative disorder (OSDD) covers presentations with clinically meaningful symptoms that do not meet the full requirements of a specific DSM dissociative diagnosis; ICD-11 includes a category of partial DID with its own requirements. Their underlying presentations and treatment targets vary. The existence of changing identity states does not imply that each state requires its own medication, and reported symptoms or an online questionnaire cannot establish DID.
Dissociative amnesia, PTSD-related dissociation, and other presentations
Dissociative amnesia involves difficulty recalling important autobiographical information that cannot be explained by ordinary forgetting alone; it requires evaluation for neurological, substance-related, sleep, and other psychiatric causes. PTSD can include dissociative symptoms, but treatment evidence in PTSD populations addresses PTSD-specific questions and should not be transferred directly to DID or primary DPDR disorder. Functional neurological symptoms, panic, psychosis, ADHD-related inattention, and medication-associated cognitive problems each require their own assessment. A memory gap also does not establish the historical cause of the gap.
What medications have been studied?
SSRIs: fluoxetine, paroxetine, and related antidepressants
Selective serotonin reuptake inhibitors (SSRIs) treat established indications such as some depressive and anxiety disorders and certain PTSD presentations. Their effect on depersonalization itself is a different question. In a randomized fluoxetine trial, 50 participants were assigned to fluoxetine or placebo for ten weeks. Fluoxetine did not show clinically meaningful superiority on the main depersonalization outcomes; improvements in co-occurring anxiety were associated with improvements in depersonalization for some individuals. This is not evidence that fluoxetine is an established primary DPDR treatment.
A separate placebo-controlled paroxetine trial in chronic PTSD reported improvement in PTSD and dissociation scale outcomes. Importantly, participants had PTSD as the primary diagnosis. Its findings support asking whether treating co-occurring PTSD can reduce associated dissociative symptoms. They do not prove paroxetine treats DID, dissociative amnesia, or primary DPDR. The pharmacotherapy systematic review similarly warned against overinterpreting diverse small trials.
SSRIs may bring nausea, sleep changes, agitation, sexual side effects, and sometimes emotional blunting; clinicians also monitor for activation, suicidality concerns in younger patients, interactions, and manic symptoms in susceptible individuals. A person who feels emotionally distant after a medication change should describe the timing and quality of that change rather than automatically assuming the dissociative disorder has worsened. An antidepressant should not be stopped abruptly without a prescribing plan.
Lamotrigine: why two trials produced different findings
Lamotrigine, an anticonvulsant also used in selected mood-disorder treatment, was investigated partly because researchers hypothesized that glutamatergic signaling might be involved in depersonalization. In a small randomized crossover trial of nine participants, lamotrigine was not superior to placebo. In another randomized study published in 2011, investigators reported a substantial apparent advantage over placebo, but the study had extensive attrition and its findings require independent replication. A retrospective add-on series of 32 patients also reported improvement for some patients, but its uncontrolled design cannot separate drug effects from concurrent antidepressants, clinical selection, placebo responses, or natural change.
The systematic review of randomized DPDR interventions found inconsistent lamotrigine evidence and called for further research. Lamotrigine is not an established dissociation-specific treatment. Its adverse-effect profile is consequential: MedlinePlus prescribing information warns about potentially life-threatening rashes, especially with inappropriate initiation or rapid dose escalation and certain interacting medications. Rash, mouth sores, blistering, or systemic illness after starting the drug requires prompt medical assessment. This is a specialist prescribing decision, not a self-experiment.
Naltrexone, naloxone, and the opioid-system hypothesis
One research hypothesis proposes that endogenous opioid signaling contributes to a subset of dissociative phenomena. Naltrexone and naloxone block opioid receptors through different formulations and clinical uses; they are distinct medications and their evidence cannot simply be combined as if they were the same intervention. In an open-label naltrexone study of 14 depersonalization patients, symptoms declined on average during treatment, but there was no placebo control. Improvement in such a study cannot demonstrate causal efficacy.
A 2011 pair of small randomized crossover trials in borderline personality disorder studied a total of 29 patients. Dissociative symptom measures were numerically lower with naltrexone than with placebo, but the effects did not reach statistical significance. A 2023 systematic review and meta-analysis of opioid antagonists pooled five comparative studies and 154 participants, estimating an apparently large overall reduction; the review explicitly flagged marked heterogeneity, study-quality limitations, and possible publication bias. This creates a research rationale, not a validated routine prescription for dissociative disorders.
Naltrexone has established uses in alcohol and opioid use disorders, but a dissociation indication remains investigational/off-label where considered. It can block opioid pain medicines and precipitate withdrawal in opioid-dependent patients; pain treatment, surgery, opioid exposure, liver disease, and interactions must be reviewed before prescribing. The National Library of Medicine drug guidance details these risks. Naloxone is widely used to reverse opioid overdose; small dissociation studies do not turn emergency naloxone into a home treatment for feeling unreal.
Benzodiazepines and sedating medicines
A clinician may sometimes prescribe an anxiolytic for a separately diagnosed condition or a time-limited acute problem. That does not establish that benzodiazepines treat dissociative pathology. Sedation, impaired concentration and memory, dependence, interactions with other depressants, and withdrawal can complicate evaluation of dissociation. A sense of detachment that begins after a sedative change calls for medication review. In trauma-related care, benzodiazepine decisions must follow the evidence and guidance for the diagnosed condition, rather than using the presence of dissociation alone as an indication.
Antipsychotics, mood stabilizers, sleep medicines, and other drugs
Antipsychotics may be indicated for a separately assessed psychotic or bipolar disorder, or another evidence-supported indication. Hearing internally experienced voices or describing altered identity does not itself establish schizophrenia, and dissociation should not automatically be treated with antipsychotic medication. Sedation, movement disorders, metabolic effects, and interactions require individual risk assessment. Likewise, mood stabilizers are used when an actual mood disorder warrants them; hypnotics or sleep-focused treatments address sleep complaints, not the entire dissociative syndrome.
Small studies and clinical anecdotes discuss additional agents, but no consistent replicated evidence supports a universal medication algorithm for dissociative amnesia, identity alteration, memory gaps, or depersonalization. Off-label treatment is a medical decision informed by indication, alternatives, risks, treatment response, and patient preference. A medicine's biological plausibility is not a clinical efficacy finding.
Evidence at a glance: What has and has not been established?
SSRIs: an individual with depression, anxiety, or PTSD may benefit when that condition is appropriately treated. For primary DPDR, the randomized fluoxetine study was negative; paroxetine findings in PTSD do not transfer to other dissociative diagnoses. Status: established use for separate indications; limited, mixed direct antidissociative evidence.
Lamotrigine: small randomized studies disagree, and observational add-on results are insufficient to resolve the discrepancy. Status: experimental for DPDR; potentially serious rash risk.
Naltrexone and related opioid antagonists: mechanistic rationale and limited clinical signals, including heterogeneous positive pooled findings and a nonsignificant controlled BPD trial. Status: preliminary and investigational for dissociation; important opioid and liver-related safety issues.
Benzodiazepines, antipsychotics, and other psychiatric drugs: they may treat distinct assessed conditions, but their use should not be interpreted as proof of a dissociative-disorder indication. Status: comorbidity-specific prescribing; direct evidence insufficient. These evidence categories are based on the 2019 pharmacotherapy review, 2023 DPDR synthesis, and 2023 opioid-antagonist synthesis.
Can treating another condition reduce dissociation?
Sometimes. Co-occurring depression, anxiety, PTSD, panic, insomnia, pain, and substance-related problems can influence distress, functioning, and the frequency or intensity of dissociative experiences. A medication that successfully treats a well-assessed co-occurring condition may indirectly improve everyday stability or reduce triggering states. The clinician should define in advance whether the target is depressed mood, panic frequency, nightmares, sleep, intrusive PTSD symptoms, or dissociation itself, because these are different outcomes.
If derealization occurs mainly during panic episodes, a carefully selected anxiety treatment may reduce the episodes even if it has no direct effect on derealization mechanisms. If a person has persistent DPDR independently of anxiety, anxiety improvement alone may be insufficient. If medication causes fatigue or emotional numbing, a patient might report being less distressed while continuing to feel disconnected. Both symptom frequency and the ability to function matter.
PTSD-associated dissociation must be understood in the context of PTSD assessment and treatment, while borderline-personality-associated dissociation requires a different diagnostic formulation. Drug evidence gathered in those populations cannot be used to diagnose either condition. For a published English guide to PTSD as its own canonical topic, see Posttraumatic Stress Disorder: Symptoms, Diagnosis, and Treatment.
Does medication work differently for DID, OSDD, DPDR, and dissociative amnesia?
For DID and related identity disorders
The 2011 ISSTD guideline advises treating co-occurring disorders and troublesome associated symptoms while recognizing that medication is not the core intervention for identity discontinuity, amnesia, or complex dissociative processes. The guideline is expert consensus informed by available studies; it should not be mistaken for a large randomized drug-trial evidence base. Medication adherence, varying reports of side effects, polypharmacy, and coordination between the prescriber and psychotherapist can be particularly important.
Clinical teams should agree on a single medication list and a practical method for tracking doses and effects. Memory difficulties can complicate whether a medicine was taken, and accidental double dosing is a safety issue. One body takes one prescribed regimen; distinct identity states do not imply separate physiological dosing requirements. Discuss uncertain adherence openly, with support and safety planning as appropriate.
For depersonalization-derealization disorder
DPDR-specific pharmacological research is more developed than for some other dissociative diagnoses, but it remains small. Lamotrigine results conflict, the fluoxetine placebo trial was negative, and opioid antagonists have not crossed the threshold into a well-validated standard treatment. The 2023 review recommends stronger studies rather than a preferred drug. Medication may still be clinically useful for independently diagnosed anxiety, depressive, mood, or other conditions, with outcomes monitored separately.
For dissociative amnesia
There is no established medication that reliably restores inaccessible autobiographical memory or verifies the origin of memory gaps. Assessment includes neurological disorders, seizures, head injury, substance effects, sleep disorders, and other relevant causes. Treating a co-occurring condition can improve functioning, but memory that appears during treatment is not automatic proof of past events. Suggestive attempts to elicit supposedly hidden memories can contaminate recall and should not be presented as evidence-based pharmacological therapy.
Why evidence is difficult to interpret
Dissociation is measured using different scales and interviews, sometimes across populations whose core diagnoses differ. Trials can count a decline in a self-report scale as improvement without establishing change in functional impairment, diagnostic status, or long-term recovery. A 2026 umbrella review of dissociation conceptualization and assessment summarized substantial disagreement about how dissociation is conceptualized and measured. These uncertainties matter when comparing drug studies.
Placebo effects, regression toward the mean, fluctuating symptoms, overlapping PTSD or BPD symptoms, concurrent psychotherapy, dropout, and small samples can make uncontrolled treatment changes look more definitive than they are. A non-significant trial is not proof that no individual can ever benefit, while a favorable open-label result is not proof that a medication works. Replicated, adequately powered, diagnosis-specific randomized trials with clinically meaningful outcomes are necessary.
What role does psychotherapy have?
Clinical care often emphasizes a careful therapeutic relationship, symptom education, emotion regulation, grounding where helpful, and treatments adapted to the individual's presentation. For complex dissociative disorders, some specialist guidelines advocate phased, trauma-informed therapy, but treatment protocols and the strength of evidence remain under study. A 2025 systematic review of phase-oriented treatment and a 2024 systematic review of psychotherapy for dissociative symptoms found reports of improvement, while highlighting limitations that preclude confident comparisons among specific psychotherapies.
Patients need not be pushed into rapid trauma-memory exploration or told that every symptom reveals an undiscovered traumatic event. Care should prioritize safety, shared goals, present-day functioning, and accurate assessment. When dissociation appears during sessions, clinicians can adjust pace and stabilization strategies. Medication can sometimes be an adjunct that improves sleep, mood, or readiness to participate, without being described as the mechanism that resolves identity disruption.
Could a medication cause or worsen dissociative feelings?
Yes, some prescription medicines, intoxication states, withdrawal states, and drug interactions can produce emotional blunting, altered perception, confusion, sedation, or memory problems. These experiences may be described as feeling detached, unreal, or absent even when a dissociative disorder is not the underlying explanation. Effects depend on the substance, dose, timing, and the person's medical context. Recreational dissociative drugs and cannabis-related depersonalization require their own substance-related assessment.
A useful medication timeline records the symptom pattern before treatment; starting or changing dates; missed doses; combinations with alcohol, cannabis, opioid drugs or sedatives; sleep changes; and any dose-related deterioration. The purpose is to support a clinician's differential assessment, not to invite an unsupervised discontinuation trial. Stopping some medicines abruptly can produce withdrawal or relapse, and a sudden increase in confusion or altered awareness merits medical evaluation.
How clinicians decide whether to prescribe
First, a clinician assesses whether the experiences represent transient stress-related dissociation, a persistent dissociative disorder, a dissociative symptom within another condition, medication effects, a neurological disorder, or several overlapping factors. New episodes of impaired consciousness, convulsions, delirium, severe headache, focal neurological changes, intoxication, or significant injuries warrant urgent medical evaluation rather than attribution to dissociation.
Next, the prescriber and patient identify a concrete treatment target, expected benefit, available alternatives, safety risks, and how response will be assessed. A symptom diary can distinguish mood, panic, sleep, depersonalization intensity, memory continuity, and functioning. The follow-up plan should state how adverse effects, adherence, unexpected worsening, and combinations of medicines will be reviewed. Screening tools can track severity but never replace a diagnostic interview.
Informed consent is particularly important when a medication is being considered off-label for a dissociative complaint. The discussion should specify that the indication is experimental, acknowledge negative or conflicting trials, address risks and costs, and clarify how clinical benefit would be evaluated. A second specialist opinion can be reasonable for complex presentations, treatment-resistant symptoms, or multiple medications.
Safety: When to seek immediate medical care
Urgent medical assessment is appropriate for a first seizure or loss of consciousness, sudden confusion with inability to stay oriented, new weakness or speech problems, serious intoxication or overdose, or a potentially severe drug reaction. People taking lamotrigine should seek prompt assessment for a new rash or associated systemic symptoms because serious skin reactions are possible. Those prescribed naltrexone must tell healthcare professionals about opioid use and planned surgery; attempts to override opioid blockade can be dangerous.
If suicidal thoughts, severe self-neglect, or an immediate threat to safety develops, seek local emergency services or crisis care. A dissociative label does not replace an examination for potentially urgent physical or psychiatric causes. People should avoid driving or other hazardous tasks during episodes involving impaired awareness or after taking a medicine that impairs alertness.
Practical questions to discuss with your prescriber
Ask which diagnosis or symptom the medication is intended to treat; whether the evidence involves your specific disorder or a different population; what response would look like in your daily life; how long a monitored trial would last; which adverse effects or interactions need attention; and what the alternative treatment plan is if the drug is ineffective. Bring all prescriptions, over-the-counter drugs, supplements, alcohol or substance use information, and relevant medical history. A clinician can then make a decision with the person rather than from a single dissociation score.
If you already take a psychiatric medication and still experience dissociation, that does not necessarily mean treatment has failed. The medicine may be benefiting a separate condition, or the experience may have another cause. Review the pattern with the prescriber and consider whether specialized psychological assessment is appropriate. Avoid adding an internet-recommended medication or changing doses based solely on a small experimental study.
Frequently Asked Questions
Is there a best medication for dissociation?
No medication has established broad efficacy across dissociative disorders. Individual prescriptions should be tied to a diagnosed condition and defined treatment target. Existing medication studies are heterogeneous, small, and frequently inconclusive.
Can antidepressants stop derealization?
They may help anxiety or depression that accompanies derealization, and reducing those symptoms may change how often detachment occurs. A randomized study did not establish fluoxetine as an effective treatment for primary depersonalization disorder. Persistent derealization warrants assessment rather than assuming an antidepressant is the solution.
Do SSRIs help dissociative identity disorder?
SSRIs can be prescribed for a co-occurring depression, anxiety disorder, or another established indication. There is no adequate evidence that SSRIs directly resolve DID identity discontinuity or amnesia. Treatment planning depends on a comprehensive clinical assessment.
Is lamotrigine recommended for depersonalization?
Trials have yielded conflicting results, and the evidence is insufficient to establish it as routine treatment for DPDR. Lamotrigine requires medical prescribing and monitoring because of potentially severe rash and drug interactions.
Does naltrexone treat dissociation?
Some small and heterogeneous studies suggest a possible benefit, while a controlled trial in BPD found no statistically significant advantage over placebo. It remains investigational for dissociative symptoms. It can interfere dangerously with opioid medications and requires an appropriate medical review.
Are benzodiazepines a treatment for dissociative episodes?
They are not an established direct treatment for dissociative disorders. They may be used for another clinically appropriate indication, but sedation, memory effects, dependence, and withdrawal can complicate the picture. New or worsening episodes should prompt review of all medicines and other causes.
Can medication recover memories lost to dissociative amnesia?
No validated medication can reliably recover autobiographical memories or prove that a recovered narrative reflects historical events. Investigating memory gaps requires a careful differential assessment and avoidance of suggestive recall procedures.
Is dissociation a side effect of antidepressants?
Some people describe emotional blunting, unreality, dizziness, or altered awareness after treatment changes, but such sensations have multiple possible causes. A clinician can assess timing, differential diagnoses, dose, interactions, and benefits. Do not abruptly stop a prescribed antidepressant.
Does medication work better with therapy?
Combined treatment may be appropriate when a co-occurring condition has a medication indication and the person is also receiving condition-sensitive psychotherapy. Research does not yet establish a universal medication-plus-therapy protocol for all dissociative diagnoses.
Do dissociative symptoms always come from trauma?
No. Trauma is an important clinical association in many populations, but detachment or memory disturbances can occur in other medical, psychiatric, substance-related, and everyday circumstances. Symptom history, functional impact, and differential assessment determine the formulation.
How can I tell if medication is helping?
Track concrete outcomes such as functioning, symptom frequency and duration, sleep, mood, anxiety, awareness gaps, and side effects with your clinician. Improvement in one area does not establish improvement in another. Screening scores and self-report observations help monitor change but are not diagnoses.
Should I stop medication if dissociation worsens?
Contact the prescriber promptly for a medication and safety review. Abrupt discontinuation can cause withdrawal or recurrence of the treated condition. Seek urgent medical help for major confusion, neurological changes, overdose symptoms, severe rash, or immediate safety concerns.
Related Articles
References
Aliyev, N. A., & Aliyev, Z. N. (2011). Lamotrigine in the immediate treatment of outpatients with depersonalization disorder without psychiatric comorbidity: Randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology, 31(1), 61–65. https://doi.org/10.1097/JCP.0b013e31820428e1.
American Psychiatric Association. (n.d.). What are dissociative disorders? https://www.psychiatry.org/patients-families/dissociative-disorders/what-are-dissociative-disorders.
Aujoulat, C., Vancappel, A., & Tapia, G. (2024). Effectiveness of psychotherapy on dissociative symptoms in adult populations: A PRISMA systematic review. L'Encéphale, 50(6), 670–681. https://doi.org/10.1016/j.encep.2024.01.001.
Escamilla, I., Juan, N., Peñalva, C., Sánchez-Llorens, M., Renau, J., Benito, A., & Haro, G. (2023). Treatment of dissociative symptoms with opioid antagonists: A systematic review. European Journal of Psychotraumatology, 14(2), 2265184. https://doi.org/10.1080/20008066.2023.2265184.
Garofalo, C., et al. (2026). The conceptualization and assessment of dissociation: An umbrella review of synthesis studies. Clinical Psychology Review. https://doi.org/10.1016/j.cpr.2026.102702.
Griffiths, T. A., et al. (2025). Effectiveness of phase-oriented treatment for trauma-related dissociative disorders: A systematic review. European Journal of Psychotraumatology. https://doi.org/10.1080/20008066.2025.2545734.
International Society for the Study of Trauma and Dissociation. (2011). Guidelines for treating dissociative identity disorder in adults, third revision. Journal of Trauma & Dissociation, 12(2), 115–187. https://www.isst-d.org/publications-resources/resources-for-professionals/adult-treatment-guidelines/.
Marshall, R. D., et al. (2007). A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety, 24(2), 77–84. https://doi.org/10.1002/da.20176.
National Library of Medicine. (n.d.). Lamotrigine: Drug information. MedlinePlus. https://medlineplus.gov/druginfo/meds/a695007.html.
National Library of Medicine. (n.d.). Naltrexone: Drug information. MedlinePlus. https://medlineplus.gov/druginfo/meds/a685041.html.
Schmahl, C., et al. (2012). Evaluation of naltrexone for dissociative symptoms in borderline personality disorder. International Clinical Psychopharmacology, 27(1), 61–68. https://doi.org/10.1097/YIC.0b013e32834d0e50.
Sierra, M., et al. (2003). A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder. Journal of Psychopharmacology, 17(1), 103–105. https://doi.org/10.1177/0269881103017001712.
Sierra, M., et al. (2006). Lamotrigine as an add-on treatment for depersonalization disorder: A retrospective study of 32 cases. Clinical Neuropharmacology, 29(5), 253–258. https://pubmed.ncbi.nlm.nih.gov/16960469/.
Simeon, D., et al. (2004). Fluoxetine therapy in depersonalisation disorder: Randomised controlled trial. British Journal of Psychiatry, 185, 31–36. https://doi.org/10.1192/bjp.185.1.31.
Simeon, D., et al. (2005). An open trial of naltrexone in the treatment of depersonalization disorder. Journal of Clinical Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/15876908/.
Somer, E., Amos-Williams, T., & Stein, D. J. (2013). Evidence-based treatment for depersonalisation-derealisation disorder (DPRD). BMC Psychology, 1, 20. https://doi.org/10.1186/2050-7283-1-20.
Sutar, R., & Sahu, S. (2019). Pharmacotherapy for dissociative disorders: A systematic review. Psychiatry Research, 281, 112529. https://doi.org/10.1016/j.psychres.2019.112529.
Wang, S., et al. (2024). The treatment of depersonalization-derealization disorder: A systematic review. Journal of Trauma & Dissociation, 25(1), 6–29. https://doi.org/10.1080/15299732.2023.2231920.
World Health Organization. (2024). Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. https://www.who.int/publications/i/item/9789240077263.